Astrazeneca Oxford Coronavirus Vaccine
- All
- News
- Videos
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
-
Two Doses Mostly Prevent Hospitalisation With Delta Variant: UK Body
Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.
-
Britain Seeks Extra AstraZeneca Shots To Combat "Beta" COVID-19 Variant
Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.
-
Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds
A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Clotting Linked With AstraZeneca Vaccine Very Rare, Says Oxford Study
The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.
-
Two Doses Mostly Prevent Hospitalisation With Delta Variant: UK Body
Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.
-
Britain Seeks Extra AstraZeneca Shots To Combat "Beta" COVID-19 Variant
Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.
-
Even Single Vaccine Dose Cuts COVID-19 Infection Rate, New UK Study Finds
A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.
